Raphael A Nemenoff

List of Publications by Year
in descending order

66 papers	3,501 citations	147801 31 h-index	149698 56 g-index
73 all docs	73 docs citations	73 times ranked	5632 citing authors

#	Article	IF	Citations
1	Heterogeneous subpopulations of adventitial progenitor cells regulate vascular homeostasis and pathological vascular remodelling. Cardiovascular Research, 2022, 118, 1452-1465.	3.8	18
2	Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. IScience, 2022, 25, 103697.	4.1	16
3	15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. American Journal of Physiology - Renal Physiology, 2022, 322, F105-F119.	2.7	8
4	On clustering for cell-phenotyping in multiplex immunohistochemistry (mIHC) and multiplexed ion beam imaging (MIBI) data. BMC Research Notes, 2022, 15, .	1.4	7
5	Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. Journal of Thoracic Oncology, 2021, 16, 486-491.	1.1	0
6	Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. , 2021, 9, e002585.		16
7	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 41.	5.4	22
8	Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. Journal of Thoracic Oncology, 2021, 16, 1694-1704.	1.1	12
9	Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. Journal of Translational Medicine, 2021, 19, 43.	4.4	17
10	PTEN (Phosphatase and Tensin Homolog) Protects Against Ang II (Angiotensin II)-Induced Pathological Vascular Fibrosis and Remodelingâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 394-403.	2.4	27
11	Complement and Cancerâ€"A Dysfunctional Relationship?. Antibodies, 2020, 9, 61.	2.5	10
12	Cancer Cellâ€"Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Antiâ€"PD-1 Therapy in Lung Adenocarcinoma. Journal of Immunology, 2020, 204, 2295-2307.	0.8	83
13	High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog). Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1854-1869.	2.4	16
14	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. , 2020, 8, e000441.		28
15	Smooth muscleâ€"derived progenitor cell myofibroblast differentiation through KLF4 downregulation promotes arterial remodeling and fibrosis. JCI Insight, 2020, 5, .	5.0	33
16	Complement factor Hâ€"deficient mice develop spontaneous hepatic tumors. Journal of Clinical Investigation, 2020, 130, 4039-4054.	8.2	30
17	Eicosanoids in Cancer: New Roles in Immunoregulation. Frontiers in Pharmacology, 2020, 11, 595498.	3.5	68
18	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Frontiers in Immunology, 2019, 10, 954.	4.8	89

#	Article	IF	Citations
19	Activation of PPARÎ³ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFÎ²1. Molecular Cancer Research, 2019, 17, 1748-1758.	3.4	12
20	Renal double negative T cells: unconventional cells in search of a function. Annals of Translational Medicine, 2019, 7, S342-S342.	1.7	6
21	Subcellular Localization and Activity of the Mitogen-Activated Protein Kinase Kinase 7 (MKK7)<i>Î³</i>Isoform are Regulated through Binding to the Phosphatase Calcineurin. Molecular Pharmacology, 2019, 95, 20-32.	2.3	6
22	Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. American Journal of Physiology - Renal Physiology, 2019, 316, F732-F742.	2.7	13
23	Tumor-intrinsic response to IFNÎ³ shapes the tumor microenvironment and antiâ€"PD-1 response in NSCLC. Life Science Alliance, 2019, 2, e201900328.	2.8	38
24	Bone marrow-derived cPLA2Î± contributes to renal fibrosis progression. Journal of Lipid Research, 2018, 59, 380-390.	4.2	8
25	A Beginnerâ€™s Guide to Analyzing and Visualizing Mass Cytometry Data. Journal of Immunology, 2018, 200, 3-22.	0.8	130
26	Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. OncoImmunology, 2018, 7, e1423182.	4.6	17
27	Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Research, 2018, 78, 143-156.	0.9	94
28	CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney International, 2018, 94, 1127-1140.	5.2	54
29	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research, 2018, 24, 5368-5380.	7.0	189
30	Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Research, 2018, 78, 4971-4983.	0.9	23
31	Adenoviral vectors transduce alveolar macrophages in lung cancer models. OncoImmunology, 2018, 7, e1438105.	4.6	13
32	Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. OncoImmunology, 2017, 6, e1356153.	4.6	89
33	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunology Research, 2017, 5, 767-777.	3.4	120
34	Differentiated Smooth Muscle Cells Generate a Subpopulation of Resident Vascular Progenitor Cells in the Adventitia Regulated by Klf4. Circulation Research, 2017, 120, 296-311.	4.5	152
35	Label-free fluorescence lifetime and second harmonic generation imaging microscopy improves quantification of experimental renalÂfibrosis. Kidney International, 2016, 90, 1123-1128.	5.2	58
36	Never make assumptions: theÂcomplicated role of complement in urinary tractÂinfections. Kidney International, 2016, 90, 469-471.	5.2	4

#	Article	IF	Citations
37	Cytosolic phospholipase A2Î± increases proliferation and de-differentiation of human renal tubular epithelial cells. Prostaglandins and Other Lipid Mediators, 2016, 126, 1-8.	1.9	5
38	Nuclear PTEN functions as an essential regulator of SRF-dependent transcription to control smooth muscle differentiation. Nature Communications, 2016, 7, 10830.	12.8	53
39	Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer. Journal of Immunology, 2016, 196, 2847-2859.	0.8	86
40	Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. Journal of Immunology, 2016, 196, 891-901.	0.8	66
41	Activation of the Retinoid X Receptor Modulates Angiotensin II-Induced Smooth Muscle Gene Expression and Inflammation in Vascular Smooth Muscle Cells. Molecular Pharmacology, 2014, 86, 570-579.	2.3	10
42	Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2014, 12, 1460-1469.	3.4	38
43	Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional and Epigenetic Control of E-Cadherin Expression. Cancer Research, 2014, 74, 7357-7370.	0.9	42
44	Transmigrating Neutrophils Shape the Mucosal Microenvironment through Localized Oxygen Depletion to Influence Resolution of Inflammation. Immunity, 2014, 40, 66-77.	14.3	373
45	Eicosanoid Profiling in an Orthotopic Model of Lung Cancer Progression by Mass Spectrometry Demonstrates Selective Production of Leukotrienes by Inflammatory Cells of the Microenvironment. PLoS ONE, 2013, 8, e79633.	2.5	50
46	Anti- and Protumorigenic Effects of PPARÎ³in Lung Cancer Progression: A Double-Edged Sword. PPAR Research, 2012, 2012, 1-12.	2.4	5
47	Activation of PPARÎ³ in myeloid cells promotes lung cancer progression and metastasis. OncoImmunology, 2012, 1, 403-404.	4.6	7
48	Activation of PPARÎ³ in Myeloid Cells Promotes Lung Cancer Progression and Metastasis. PLoS ONE, 2011, 6, e28133.	2.5	60
49	SDF-1Î± Induction in Mature Smooth Muscle Cells by Inactivation of PTEN Is a Critical Mediator of Exacerbated Injury-Induced Neointima Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1300-1308.	2.4	118
50	Peroxisome Proliferator-Activated Receptor-Î³ Inhibits Transformed Growth of Non-Small Cell Lung Cancer Cells through Selective Suppression of Snail. Neoplasia, 2010, 12, 224-IN4.	5.3	36
51	Prostacyclin Inhibits Non-Small Cell Lung Cancer Growth by a Frizzled 9-Dependent Pathway That Is Blocked by Secreted Frizzled-Related Protein 1. Neoplasia, 2010, 12, 244-IN6.	5.3	43
52	Depletion of Cytosolic Phospholipase A2 in Bone Marrowâ€"Derived Macrophages Protects against Lung Cancer Progression and Metastasis. Cancer Research, 2009, 69, 1733-1738.	0.9	68
53	Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-Î³ in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-ÎºB. Molecular Pharmacology, 2008, 73, 709-717.	2.3	60
54	Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferatorâ€"Activated Receptor Î³. Cancer Prevention Research, 2008, 1, 349-356.	1.5	73

#	Article	IF	Citations
55	Targeted Deletion of PTEN in Smooth Muscle Cells Results in Vascular Remodeling and Recruitment of Progenitor Cells Through Induction of Stromal Cellâ€“Derived Factor-1Î±. Circulation Research, 2008, 102, 1036-1045.	4.5	99
56	Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>Ligands in Lung Cancer. PPAR Research, 2008, 2008, 1-8.	2.4	25
57	Peroxisome Proliferator-Activated Receptor-Î³ in Lung Cancer: Defining Specific Versus â€œOff-Targetâ€• Effectors. Journal of Thoracic Oncology, 2007, 2, 989-992.	1.1	28
58	Peroxisome proliferator-activated receptor-Î³ (PPARÎ³) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene, 2005, 24, 1412-1422.	5.9	106
59	Role of nuclear receptors in lung tumourigenesis. European Journal of Cancer, 2005, 41, 2561-2568.	2.8	30
60	Peroxisome Proliferator-Activated Receptor-Î³ Is a Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth. Molecular Pharmacology, 2002, 62, 1207-1214.	2.3	137
61	Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Research, 2002, 62, 734-40.	0.9	113
62	Increased renal and vascular cytosolic phospholipase A2activity in rats with cirrhosis and ascites. Hepatology, 1998, 27, 42-47.	7.3	17
63	Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer. Journal of Biological Chemistry, 1997, 272, 14501-14504.	3.4	144
64	Characterization of Phospholipase A₂ Activity Enriched in the Nerve Growth Cone. Journal of Neurochemistry, 1996, 67, 2599-2608.	3.9	40
65	Tyrosine kinase growth factor receptors but not seven-membraneâ€“spanning receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. Hepatology, 1995, 22, 1296-1303.	7.3	19
66	Activation of a novel form of phospholipase A2during liver regeneration. FEBS Letters, 1995, 367, 228-232.	2.8	10